IFNG and COVID-19: Although the mechanisms of immune-related adverse events of checkpoint inhibitors are not completely elucidated, it is conceivable that the similar pattern of multiorgan damage found in COVID-19 patients may result from common pathogenetic mechanisms including T-cell activation with consequent T-cell proliferation and multiorgan infiltration, reduction of Treg function and survival, production of cytokines such as IL-17A, TNF, IFNγ and IL-2 [10].